ORIGINAL ARTICLE
Wheezing in preterm infants and children
Eli Rhoads MD,
Gregory S. Montgomery MD,
Clement L. Ren MD, MBA,
Eli Rhoads MD
Division of Pediatric Pulmonology, Allergy, and Sleep Medicine, Riley Hospital for Children, Indianapolis, Indiana, USA
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA
Search for more papers by this authorGregory S. Montgomery MD
Division of Pediatric Pulmonology, Allergy, and Sleep Medicine, Riley Hospital for Children, Indianapolis, Indiana, USA
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA
Search for more papers by this authorCorresponding Author
Clement L. Ren MD, MBA
Division of Pediatric Pulmonology, Allergy, and Sleep Medicine, Riley Hospital for Children, Indianapolis, Indiana, USA
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA
Correspondence Clement L. Ren, MD, MBA, Riley Hospital for Children, ROC 4270, 705 Riley Hospital Drive, Indianapolis, IN 46202, USA.
Email: [email protected]
Search for more papers by this authorEli Rhoads MD,
Gregory S. Montgomery MD,
Clement L. Ren MD, MBA,
Eli Rhoads MD
Division of Pediatric Pulmonology, Allergy, and Sleep Medicine, Riley Hospital for Children, Indianapolis, Indiana, USA
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA
Search for more papers by this authorGregory S. Montgomery MD
Division of Pediatric Pulmonology, Allergy, and Sleep Medicine, Riley Hospital for Children, Indianapolis, Indiana, USA
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA
Search for more papers by this authorCorresponding Author
Clement L. Ren MD, MBA
Division of Pediatric Pulmonology, Allergy, and Sleep Medicine, Riley Hospital for Children, Indianapolis, Indiana, USA
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA
Correspondence Clement L. Ren, MD, MBA, Riley Hospital for Children, ROC 4270, 705 Riley Hospital Drive, Indianapolis, IN 46202, USA.
Email: [email protected]
Search for more papers by this authorAbstract
Wheezing is a common outcome of preterm birth. This article will review the mechanisms, epidemiology, and treatment of wheezing in preterm children with and without a history of bronchopulmonary dysplasia.
CONFLICTS OF INTERESTS
Eli Rhoads has no conflicts of interest to disclose. Gregory Montgomery has no conflicts of interest to disclose. Clement L Ren has no conflicts of interest to disclose.
Open Research
DATA AVAILABILITY STATEMENT
Data derived from public domain resources.
REFERENCES
- 1Islam JY, Keller RL, Aschner JL, Hartert TV, Moore PE. Understanding the short- and long-term respiratory outcomes of prematurity and bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2015; 192: 134-156.
- 2Busse WW, Lemanske RF. Asthma. N Engl J Med. 2001; 344: 350-362.
- 3Pijnenburg MWH, De, Jongste JC. Exhaled nitric oxide in childhood asthma: a review. Clin Exp Allergy. 2008; 38: 246-259.
- 4Baraldi E, Bonetto G, Zacchello F, Filippone M. Low exhaled nitric oxide in school-age children with bronchopulmonary dysplasia and airflow limitation. Am J Respir Crit Care Med. 2005; 171: 68-72.
- 5Hysinger E, Friedman N, Jensen E, Zhang H, Piccione J. Bronchoscopy in neonates with severe bronchopulmonary dysplasia in the NICU. J Perinatol. 2019; 39: 263-268.
- 6Doyle LW, Carse E, Adams AM, Ranganathan S, Opie G, Cheong JLY. Ventilation in extremely preterm infants and respiratory function at 8 years. N Engl J Med. 2017; 377: 329-337.
- 7Colin AA, McEvoy C, Castile RG. Respiratory morbidity and lung function in preterm infants of 32 to 36 weeks' gestational age. Pediatrics. 2010; 126: 115-128.
- 8Di Fiore JM, Dylag AM, Honomichl RD, et al. Early inspired oxygen and intermittent hypoxemic events in extremely premature infants are associated with asthma medication use at 2 years of age. J Perinatol. 2019; 39: 203-211.
- 9Wang H, Jafri A, Martin RJ, et al. Severity of neonatal hyperoxia determines structural and functional changes in developing mouse airway. Am J Physiol Lung Cell Mol Physiol. 2014; 307: L295-L301.
- 10Dylag AM, Mayer CA, Raffay TM, Martin RJ, Jafri A, MacFarlane PM. Long-term effects of recurrent intermittent hypoxia and hyperoxia on respiratory system mechanics in neonatal mice. Pediatr Res. 2017; 81: 565-571.
- 11Jartti T, Gern JE. Role of viral infections in the development and exacerbation of asthma in children. J Allergy Clin Immunol. 2017; 140: 895-906.
- 12Cui TX, Maheshwer B, Hong JY, Goldsmith AM, Bentley JK, Popova AP. Hyperoxic exposure of immature mice increases the inflammatory response to subsequent rhinovirus infection: association with danger signals. J Immunol. 2016; 196: 4692-4705.
- 13Pryhuber GS. Postnatal infections and immunology affecting chronic lung disease of prematurity. Clin Perinatol. 2015; 42: 697-718.
- 14Scheible KM, Emo J, Laniewski N, et al. T cell developmental arrest in former premature infants increases risk of respiratory morbidity later in infancy. JCI Insight. 2018; 3: 3.
- 15Hibbs AM, Walsh MC, Martin RJ, et al. One-year respiratory outcomes of preterm infants enrolled in the nitric oxide (to prevent) chronic lung disease trial. J Pediatr. 2008; 153: 525-529.
- 16Moreno-Galdó A, Pérez-Yarza EG, Ramilo O, et al. Recurrent wheezing during the first 3 years of life in a birth cohort of moderate-to-late preterm infants. Pediatr Allergy Immunol. 2020; 31: 124-132.
- 17Proietti E, Riedel T, Fuchs O, et al. Can infant lung function predict respiratory morbidity during the first year of life in preterm infants? Eur Respir J. 2014; 43: 1642-1651.
- 18Stevens TP, Finer NN, Carlo WA, et al. Respiratory outcomes of the surfactant positive pressure and oximetry randomized trial (SUPPORT). J Pediatr. 2014; 165: 240-249.
- 19Taussig LM, Wright AL, Holberg CJ, Halonen M, Morgan WJ, Martinez FD. Tucson Children's Respiratory Study: 1980 to present. J Allergy Clin Immunol. 2003; 111: 111-675.
- 20Fawke J, Lum S, Kirkby J, et al. Lung function and respiratory symptoms at 11 years in children born extremely preterm: the EPICure study. Am J Respir Crit Care Med. 2010; 182: 237-245.
- 21Hacking DF, Gibson AM, Robertson C, Doyle LW. Respiratory function at age 8-9 after extremely low birthweight or preterm birth in Victoria in 1997. Pediatr Pulmonol. 2013; 48: 449-455.
- 22Hennessy EM, Bracewell MA, Wood N, et al. Respiratory health in pre-school and school age children following extremely preterm birth. Arch Dis Child. 2008; 93: 1037-1043.
- 23Kotecha SJ, Watkins WJ, Lowe J, Granell R, Henderson AJ, Kotecha S. Comparison of the associations of early-life factors on wheezing phenotypes in preterm-born children and term-born children. Am J Epidemiol. 2019; 188: 527-536.
- 24Morata-Alba J, Romero-Rubio MT, Castillo-Corullón S, Escribano-Montaner A. Respiratory morbidity, atopy and asthma at school age in preterm infants aged 32-35 weeks. Eur J Pediatr. 2019; 178: 973-982.
- 25Vrijlandt E, Reijneveld SA, Aris-Meijer JL, Bos AF. Respiratory health in adolescents born moderately-late preterm in a community-based cohort. J Pediatr. 2018; 203: 429-436.
- 26Yaacoby-Bianu K, Plonsky MT, Gur M, Bar-Yoseph R, Kugelman A, Bentur L. Effect of late preterm birth on lung clearance index and respiratory physiology in school-age children. Pediatr Pulmonol. 2019; 54: 1250-1256.
- 27Martinez FD, Morgan WJ, Wright AL, Holberg CJ, Taussig LM. Diminished lung function as a predisposing factor for wheezing respiratory illness in infants. N Engl J Med. 1988; 319: 319-1117.
- 28Dylag AM, Kopin HG, O'Reilly MA, et al. Early neonatal oxygen exposure predicts pulmonary morbidity and functional deficits at 1 year. J Pediatr. 2020; 223: 20-28.
- 29Keller RL, Feng R, DeMauro SB, et al. Bronchopulmonary dysplasia and perinatal characteristics predict 1-year respiratory outcomes in newborns born at extremely low gestational age: a prospective cohort study. J Pediatr. 2017; 187: 89-97.
- 30Håland G, Carlsen KCL, Sandvik L, Devulapalli CS, Munthe-Kaas MC, Pettersen M. Reduced lung function at birth and the risk of asthma at 10 years of age. N Engl J Med. 2006; 355: 355-1689.
- 31Martinez FD, Morgan WJ, Wright AL, Holberg C, Taussig LM. Initial airway function is a risk factor for recurrent wheezing respiratory illnesses during the first three years of life. Group Health Medical Associates. Am Rev Respir Dis. 1991: 143.
- 32Bentsen MH, Markestad T, Øymar K, Halvorsen T. Lung function at term in extremely preterm-born infants: a regional prospective cohort study. BMJ Open. 2017; 7:e016868.
- 33Ren CL, Feng R, Davis SD, et al. Tidal breathing measurements at discharge and clinical outcomes in extremely low gestational age neonates. Ann Am Thorac Soc. 2018; 15: 1311-1319.
- 34Keller RL, Eichenwald EC, Hibbs AM, et al. The randomized, controlled trial of late surfactant: effects on respiratory outcomes at 1-year corrected age. J Pediatr. 2017; 183: 19-25.
- 35Jackson WM, O'Shea TM, Allred EN, Laughon MM, Gower WA, Leviton A. Risk factors for chronic lung disease and asthma differ among children born extremely preterm. Pediatr Pulmonol. 2018; 53: 1533-1540.
- 36Amitai N, Stafler P, Blau H, et al. Palivizumab following extremely premature birth does not affect pulmonary outcomes in adolescence. Chest. 2020; 158: 660-669.
- 37Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013; 368: 1791-1799.
- 38Mochizuki H, Kusuda S, Okada K, Yoshihara S, Furuya H, Simões EAF. Palivizumab prophylaxis in preterm infants and subsequent recurrent wheezing. six-year follow-up study. Am J Respir Crit Care Med. 2017; 196: 29-38.
- 39Prais D, Kaplan E, Klinger G, et al. Short- and long-term pulmonary outcome of palivizumab in children born extremely prematurely. Chest. 2016; 149: 801-808.
- 40Simões EA, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick L, Groothuis JR. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol. 2010; 126: 256-262.
- 41Simoes EA, Groothuis JR, Carbonell-Estrany X, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr. 2007; 151: 34-42.
- 42Wenzel SE, Gibbs RL, Lehr MV, Simoes EA. Respiratory outcomes in high-risk children 7 to 10 years after prophylaxis with respiratory syncytial virus immune globulin. Am J Med. 2002; 112: 627-633.
- 43Yoshihara S, Kusuda S, Mochizuki H, Okada K, Nishima S, Simões EA. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. Pediatrics. 2013; 132: 811-818.
- 44Ryan RM, Keller RL, Poindexter BB, et al. Respiratory medications in infants < 29 weeks during the first year postdischarge: the prematurity and respiratory outcomes program (PROP) consortium. J Pediatr. 2019; 208: 148-155.
- 45Mieskonen ST, Malmberg LP, Kari MA, et al. Exhaled nitric oxide at school age in prematurely born infants with neonatal chronic lung disease. Pediatr Pulmonol. 2002; 33: 347-355.
- 46Panitch HB, Keklikian EN, Motley RA, Wolfson MR, Schidlow DV. Effect of altering smooth muscle tone on maximal expiratory flows in patients with tracheomalacia. Pediatr Pulmonol. 1990; 9: 170-176.
- 47Kao LC, Durand DJ, Nickerson BG. Effects of inhaled metaproterenol and atropine on the pulmonary mechanics of infants with bronchopulmonary dysplasia. Pediatr Pulmonol. 1989; 6: 74-80.
- 48Yuksel B, Greenough A, Maconochie I. Effective bronchodilator treatment by a simple spacer device for wheezy premature infants. Arch Dis Child. 1990; 65: 782-785.
- 49Pelkonen AS, Hakulinen AL, Turpeinen M. Bronchial lability and responsiveness in school children born very preterm. Am J Respir Crit Care Med. 1997; 156: 1178-1184.
- 50Kotecha SJ, Edwards MO, Watkins WJ, Lowe J, Henderson AJ, Kotecha S. Effect of bronchodilators on forced expiratory volume in 1 s in preterm-born participants aged 5 and over: a systematic review. Neonatology. 2015; 107: 231-240.
- 51Beresford MW, Primhak R, Subhedar NV, Shaw NJ. Randomised double blind placebo controlled trial of inhaled fluticasone propionate in infants with chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 2002; 87: F62-F63.
- 52Kugelman A, Peniakov M, Zangen S, et al. Inhaled hydrofluoalkane-beclomethasone dipropionate in bronchopulmonary dysplasia. A double-blind, randomized, controlled pilot study. J Perinatol. 2017; 37: 197-202.
- 53Pelkonen AS, Hakulinen AL, Hallman M, Turpeinen M. Effect of inhaled budesonide therapy on lung function in schoolchildren born preterm. Respir Med. 2001; 95: 565-570.
- 54Yuksel B, Greenough A. Randomised trial of inhaled steroids in preterm infants with respiratory symptoms at follow up. Thorax. 1992; 47: 910-913.
- 55Pacifici GM. Clinical pharmacology of furosemide in neonates: a review. Pharmaceuticals 2013; 6: 1094-1129.
10.3390/ph6091094 Google Scholar
- 56Kao LC, Warburton D, Sargent CW, Platzker AC, Keens TG. Furosemide acutely decreases airways resistance in chronic bronchopulmonary dysplasia. J Pediatr. 1983; 103: 624-629.
- 57Kao LC, Warburton D, Cheng MH, Cedeno C, Platzker AC, Keens TG. Effect of oral diuretics on pulmonary mechanics in infants with chronic bronchopulmonary dysplasia: results of a double-blind crossover sequential trial. Pediatrics. 1984; 74: 37-44.
Citing Literature
